AU721364B2 - Codon optimized DNA sequence for insect toxin AaIT - Google Patents
Codon optimized DNA sequence for insect toxin AaIT Download PDFInfo
- Publication number
- AU721364B2 AU721364B2 AU48372/97A AU4837297A AU721364B2 AU 721364 B2 AU721364 B2 AU 721364B2 AU 48372/97 A AU48372/97 A AU 48372/97A AU 4837297 A AU4837297 A AU 4837297A AU 721364 B2 AU721364 B2 AU 721364B2
- Authority
- AU
- Australia
- Prior art keywords
- aait
- virus
- gene
- insect
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108020004705 Codon Proteins 0.000 title claims description 137
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims description 40
- 239000002919 insect venom Substances 0.000 title claims description 7
- 101000634158 Androctonus australis Beta-insect excitatory toxin 1 Proteins 0.000 title description 168
- 241000700605 Viruses Species 0.000 claims description 128
- 241000238631 Hexapoda Species 0.000 claims description 83
- 238000000034 method Methods 0.000 claims description 32
- 241000701447 unidentified baculovirus Species 0.000 claims description 31
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 21
- 150000007523 nucleic acids Chemical group 0.000 claims description 19
- 238000012546 transfer Methods 0.000 claims description 16
- 239000013604 expression vector Substances 0.000 claims description 13
- 241000196324 Embryophyta Species 0.000 claims description 10
- 241000256248 Spodoptera Species 0.000 claims description 7
- 241000255993 Trichoplusia ni Species 0.000 claims description 7
- 230000006378 damage Effects 0.000 claims description 6
- 241000255967 Helicoverpa zea Species 0.000 claims description 4
- 241000721703 Lymantria dispar Species 0.000 claims description 4
- 241000700570 unidentified entomopoxvirus Species 0.000 claims description 4
- 241000256111 Aedes <genus> Species 0.000 claims description 2
- 241000670670 Amsacta Species 0.000 claims description 2
- 241000566553 Anagrapha falcifera Species 0.000 claims description 2
- 241000239238 Androctonus australis Species 0.000 claims description 2
- 241000537222 Betabaculovirus Species 0.000 claims description 2
- 241001124093 Chironomus luridus Species 0.000 claims description 2
- 241000255942 Choristoneura fumiferana Species 0.000 claims description 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims description 2
- 241001635274 Cydia pomonella Species 0.000 claims description 2
- 241000254022 Locusta migratoria Species 0.000 claims description 2
- 241000555303 Mamestra brassicae Species 0.000 claims description 2
- 241001415013 Melanoplus Species 0.000 claims description 2
- 241000254071 Melolontha Species 0.000 claims description 2
- 241000255969 Pieris brassicae Species 0.000 claims description 2
- 241000282806 Rhinoceros Species 0.000 claims description 2
- 241000254026 Schistocerca Species 0.000 claims description 2
- 241000701451 unidentified granulovirus Species 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 2
- 241000239239 Androctonus Species 0.000 claims 1
- 241001147381 Helicoverpa armigera Species 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 94
- 108010076504 Protein Sorting Signals Proteins 0.000 description 92
- 108090000623 proteins and genes Proteins 0.000 description 80
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 71
- 108700012359 toxins Proteins 0.000 description 43
- 239000003053 toxin Substances 0.000 description 39
- 231100000765 toxin Toxicity 0.000 description 39
- 239000012634 fragment Substances 0.000 description 37
- 101710182846 Polyhedrin Proteins 0.000 description 26
- 239000013612 plasmid Substances 0.000 description 23
- 239000002773 nucleotide Substances 0.000 description 22
- 125000003729 nucleotide group Chemical group 0.000 description 22
- 230000003612 virological effect Effects 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 21
- 238000003556 assay Methods 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 108091008146 restriction endonucleases Proteins 0.000 description 20
- 208000015181 infectious disease Diseases 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 239000002299 complementary DNA Substances 0.000 description 15
- 238000010276 construction Methods 0.000 description 14
- 238000003780 insertion Methods 0.000 description 14
- 230000037431 insertion Effects 0.000 description 14
- 108091026890 Coding region Proteins 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 108091034117 Oligonucleotide Proteins 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 12
- 239000008188 pellet Substances 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 235000005911 diet Nutrition 0.000 description 11
- 230000037213 diet Effects 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 206010033799 Paralysis Diseases 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 238000013461 design Methods 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 210000002845 virion Anatomy 0.000 description 9
- 241000256244 Heliothis virescens Species 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 7
- 102100020873 Interleukin-2 Human genes 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 108020004566 Transfer RNA Proteins 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 101710166052 Apolipophorin Proteins 0.000 description 6
- 108700010070 Codon Usage Proteins 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 101710134987 Esterase 6 Proteins 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000002458 infectious effect Effects 0.000 description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 101800002326 Adipokinetic hormone Proteins 0.000 description 5
- 241000255601 Drosophila melanogaster Species 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 230000000323 adipokinetic effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 230000001418 larval effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 108010017826 DNA Polymerase I Proteins 0.000 description 4
- 102000004594 DNA Polymerase I Human genes 0.000 description 4
- 108020003215 DNA Probes Proteins 0.000 description 4
- 239000003298 DNA probe Substances 0.000 description 4
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000257159 Musca domestica Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 4
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 4
- 108020005038 Terminator Codon Proteins 0.000 description 4
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 210000001136 chorion Anatomy 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000009585 enzyme analysis Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000255789 Bombyx mori Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000255908 Manduca sexta Species 0.000 description 3
- 206010058667 Oral toxicity Diseases 0.000 description 3
- 229920002367 Polyisobutene Polymers 0.000 description 3
- 108091006629 SLC13A2 Proteins 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 108700005078 Synthetic Genes Proteins 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 108700005077 Viral Genes Proteins 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 238000000376 autoradiography Methods 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 231100000221 frame shift mutation induction Toxicity 0.000 description 3
- 230000037433 frameshift Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 3
- 210000000087 hemolymph Anatomy 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 231100000418 oral toxicity Toxicity 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000701412 Baculoviridae Species 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 238000012270 DNA recombination Methods 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 244000141359 Malus pumila Species 0.000 description 2
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 102000003797 Neuropeptides Human genes 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 108010052164 Sodium Channels Proteins 0.000 description 2
- 102000018674 Sodium Channels Human genes 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 239000007994 TES buffer Substances 0.000 description 2
- RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000006451 grace's insect medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000013383 initial experiment Methods 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102100021546 60S ribosomal protein L10 Human genes 0.000 description 1
- LSLIRHLIUDVNBN-CIUDSAMLSA-N Ala-Asp-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN LSLIRHLIUDVNBN-CIUDSAMLSA-N 0.000 description 1
- 241001219494 Androctonus australis hector Species 0.000 description 1
- NPAVRDPEFVKELR-DCAQKATOSA-N Arg-Lys-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O NPAVRDPEFVKELR-DCAQKATOSA-N 0.000 description 1
- LJUOLNXOWSWGKF-ACZMJKKPSA-N Asn-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N LJUOLNXOWSWGKF-ACZMJKKPSA-N 0.000 description 1
- YNQMEIJEWSHOEO-SRVKXCTJSA-N Asn-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O YNQMEIJEWSHOEO-SRVKXCTJSA-N 0.000 description 1
- NVFSJIXJZCDICF-SRVKXCTJSA-N Asp-Lys-Lys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N NVFSJIXJZCDICF-SRVKXCTJSA-N 0.000 description 1
- MGSVBZIBCCKGCY-ZLUOBGJFSA-N Asp-Ser-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MGSVBZIBCCKGCY-ZLUOBGJFSA-N 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 241000951889 Autographa californica multiple nucleopolyhedrovirus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100282617 Bovine herpesvirus 1.1 (strain Cooper) gC gene Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- WVLZTXGTNGHPBO-SRVKXCTJSA-N Cys-Leu-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O WVLZTXGTNGHPBO-SRVKXCTJSA-N 0.000 description 1
- HEPLXMBVMCXTBP-QWRGUYRKSA-N Cys-Phe-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(O)=O HEPLXMBVMCXTBP-QWRGUYRKSA-N 0.000 description 1
- IRKLTAKLAFUTLA-KATARQTJSA-N Cys-Thr-Lys Chemical compound C[C@@H](O)[C@H](NC(=O)[C@@H](N)CS)C(=O)N[C@@H](CCCCN)C(O)=O IRKLTAKLAFUTLA-KATARQTJSA-N 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000255890 Galleria Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- VBOBNHSVQKKTOT-YUMQZZPRSA-N Gly-Lys-Ala Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O VBOBNHSVQKKTOT-YUMQZZPRSA-N 0.000 description 1
- UIQGJYUEQDOODF-KWQFWETISA-N Gly-Tyr-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 UIQGJYUEQDOODF-KWQFWETISA-N 0.000 description 1
- WRFOZIJRODPLIA-QWRGUYRKSA-N Gly-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)CN)O WRFOZIJRODPLIA-QWRGUYRKSA-N 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000256257 Heliothis Species 0.000 description 1
- 101001108634 Homo sapiens 60S ribosomal protein L10 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- VCSBGUACOYUIGD-CIUDSAMLSA-N Leu-Asn-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VCSBGUACOYUIGD-CIUDSAMLSA-N 0.000 description 1
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- RIJCHEVHFWMDKD-SRVKXCTJSA-N Lys-Lys-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O RIJCHEVHFWMDKD-SRVKXCTJSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241001599018 Melanogaster Species 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- 241000256259 Noctuidae Species 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108700020497 Nucleopolyhedrovirus polyhedrin Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- QCARZLHECSFOGG-CIUDSAMLSA-N Pro-Glu-Cys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O QCARZLHECSFOGG-CIUDSAMLSA-N 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 241001467043 Prune dwarf virus Species 0.000 description 1
- 241001598112 Rachiplusia ou MNPV Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000304160 Sarcophaga carnaria Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- BTPAWKABYQMKKN-LKXGYXEUSA-N Ser-Asp-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BTPAWKABYQMKKN-LKXGYXEUSA-N 0.000 description 1
- WKLJLEXEENIYQE-SRVKXCTJSA-N Ser-Cys-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O WKLJLEXEENIYQE-SRVKXCTJSA-N 0.000 description 1
- 241000187392 Streptomyces griseus Species 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- XKDOQXAXKFQWQJ-SRVKXCTJSA-N Tyr-Cys-Asp Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O XKDOQXAXKFQWQJ-SRVKXCTJSA-N 0.000 description 1
- JPPXDMBGXJBTIB-ULQDDVLXSA-N Val-His-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N JPPXDMBGXJBTIB-ULQDDVLXSA-N 0.000 description 1
- LYERIXUFCYVFFX-GVXVVHGQSA-N Val-Leu-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N LYERIXUFCYVFFX-GVXVVHGQSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002728 bioinsecticidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 108010004073 cysteinylcysteine Proteins 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001538 fat body cell Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000989 food dye Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 108010048994 glycyl-tyrosyl-alanine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 102000017941 granulin Human genes 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- YIEDSISPYKQADU-UHFFFAOYSA-N n-acetyl-n-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]acetamide Chemical compound C1=C(C)C(N(C(C)=O)C(=O)C)=CC=C1N=NC1=CC=CC=C1C YIEDSISPYKQADU-UHFFFAOYSA-N 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 238000001807 normal pulse voltammetry Methods 0.000 description 1
- 210000004492 nuclear pore Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000001769 paralizing effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000005892 protein maturation Effects 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/50—Isolated enzymes; Isolated proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Insects & Arthropods (AREA)
- Physics & Mathematics (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
S F Ref: 2611310D
AUSTRALIA
PATENTS ACT 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT
ORIGINAL
too 0 of.* :00*0 0 Name and Address of Applicant: American Cyanamid Company One CyanamiiS Plaza Wayne N 1 ew Jersey 07470 8426 UNITED STATES OF AMERICA Fiv e, F1rVJ1 0 .fyns Macke.O(N Twsej Oiq4O -Ot4 Actual Inventor(s): Bruce Christian Black, Lynn Michael Dierks Ann Brennan and Peter Address for Service: Spruson Ferguson, Patent Attorneys Level 33 St Martins Tower, 31 Market Street Sydney, New South Wales, 2000, Australia Codon Optimized DNA Sequence for Insect Toxin AaIT Invention Title: The following statement is a full description of this invention, including the best method of performing it known to me/us:- 5845 CODON OPTIMIZED DNA SEQUENCE FOR INSECT TOXIN AaIT Field of the Invention This invention relates to the construction of a codon optimized DNA sequence encoding the insect-specific toxin AaIT, to the expression of that toxin, and the demonstration of in vivo toxicity of insect viruses encoding that toxin.
Background of the Invention The following abbreviations are used throughout this application: A. cal. Autoqrapha californica AcMNPV Autocrapha californica nuclear polyhedrosis virus 15 AaIT Androctonus australis insect toxin bp base pairs CPU contractile paralysis unit ECV extracellular virus GV granulosis virus kD kilodaltons LT lethality time MOI multiplicity of infection NPV nuclear polyhedrosis virus .OB occlusion body Occ- occlusion negative virus(es) Occ+ occlusion positive virus(es) PCR polymerase chain reaction PDV polyhedron derived virus PFU plaque forming unit 2 p.i. post-infection PIB polyhedron inclusion body (also known as OB) ST survival time The family of DNA insect viruses known as Baculoviridae includes nuclear polyhedrosis viruses (NPV) and granulosis viruses These viruses produce occlusion bodies (OBs) in their life cycle.
Also included are the non-occluded viruses (NOV), which do not produce OBs in their life cycle.
Another family of DNA insect viruses are the entomopox viruses.
Over 400 baculoviruses have been identified as present in invertebrates. Examples of NPVs include Lymantria dispar NPV (gypsy moth NPV), Autographa californica MNPV, Svncrapha falcifera NPV (celery looper NPV), Spodoptera litturalis NPV, Spodoptera fruqiperda NPV, Heliothis armiqera NPV, Mamestra brassicae NPV, Choristoneura fumiferana NPV, Trichoplusia ni NPV, Helicoverpa zea NPV, etc.
20 Examples of GVs include Cvdia pomonella GV (codling moth GV), Pieris brassicae GV, Trichoplusia ni GV, etc. Examples of NOVs are Orcytes rhinoceros NOV and Heliothis zea NOV. Examples of entomopox viruses include Melolontha melonotha EPV, Amsacta moorei EPV, Locusta migratoria EPV, Melanoplus sanquinipes EPV, Schistocerca grecaria EPV, Aedes aevypti EPV, Chironomus luridus EPV, etc.
The use of baculoviruses and entomopox .viruses as bioinsecticides holds great promise. One of the major impediments to their widespread use in agriculture is the time lag between initial infection of the insect and its death. This lag can range from a few days to several weeks. During this lag, the insect continues to feed, causing further 3 damage to the plant. A number of researchers have attempted to overcome this drawback by inserting a heterologous gene into the viral genome, so as to express an insect controlling or modifying substance, such as a toxin (Bibliography entries 1,2,3).
The life cycle of baculoviruses, as exemplified by AcMNPV, includes two stages. Each stage of the life cycle is represented by a specific form of the virus: Extracellular viral particles (ECV) which are nonoccluded, and occluded virus particles (OB) The extracellular and occluded virus forms have the same genome, but exhibit different biological properties. The maturation of each of the two forms of the virus is directed by overlapping sets of viral genes, some of which are unique to each form.
In its naturally occurring insect infectious form, multiple virions are found embedded in a paracrystalline protein matrix known as an occlusion body which is also referred to as a polyhedron inclusion body (PIB). The proteinaceous viral occlusions are referred to as polyhedra (polyhedron is the singular term). A polyhedrin 25 protein, which has a molecular weight of 29 kD, is the major viral-encoded structural protein of the viral occlusions (Similarly, GVs produce OBs which are composed primarily of granulin, rather than polyhedrin).
30 The viral occlusions are an important part of the natural baculovirus life cycle, providing the means for horizontal (insect to insect) transmission among susceptible insect species. In the :'environment, a susceptible insect (usually in the larval stage) ingests the viral occlusions from a 4 contaminated food source, such as a plant. The crystalline occlusions dissociate in the gut of the susceptible insects to release the infectious viral particles. These polyhedron derived viruses (PDV) invade and replicate in the cells of the midgut tissue It is believed that virus particles enter the cell by endocytosis or fusion, and the viral DNA is uncoated at the nuclear pore or in the nucleus.
Viral DNA replication is detected within six hours.
By 10-12 hours post-infection secondary infection spreads to other insect tissues by the budding of the extracellular virus (ECV) from the surface of the cell. The ECV form of the virus is responsible for cell to cell spread of the virus within an individual infected insect, as well as transmitting infection in cell culture.
Late in the infection cycle (12 hours polyhedrin protein can be detected in infected cells. It is not until 18-24 hours p.i.
that the polyhedrin protein assembles in the nucleus of the infected cell and virus particles become embedded in the proteinaceous occlusions. Viral occlusions accumulate to large numbers over 4-5 days as cells lyse. These polyhedra have no active role in the spread of infection in the larva. ECVs in the haemolymph multiply and spread, leading to the death of the larva When infected larvae die, millions of 30 polyhedra remain in the decomposing tissue, while the ECVs are degraded. When other larvae are exposed to the polyhedra, for example, by ingestion of contaminated plants or other food material, the cycle is repeated In summary, the occluded form of the virus i 5 is responsible for the initial infection of the insect through the gut, as well as the environmental stability of the virus. PDVs are essentially not infectious when administered by injection, but are highly infectious orally. The non-occluded form of the virus ECV) is responsible for secondary and cell to cell infection. ECVs are highly infectious for cells in culture or internal insect tissues by injection, but essentially not infectious by oral administration.
The use of recombinant baculoviruses expressing foreign proteins which are toxic to insects is facilitated by the fact that these viruses are not pathogenic to vertebrates or plants.
In addition, the baculoviruses generally have a narrow host range. Many strains are limited to one or a few insect species.
The Autocrapha californica nuclear polyhedrosis virus (AcMNPV) is the prototype virus of the family Baculoviridae. The AcMNPV virus was Soriginally isolated from Autoqrapha californica (A.
cal.), a lepidopteran noctuid (which in its adult stage is a nocturnal moth), commonly known as the alfalfa looper. This virus infects 12 families and 25more than 30 species within the order of Lepidoptera insects It is not known to infect productively any species outside this order. The most widely studied baculovirus is AcMNPV. This virus utilizes many of the protein maturation and transport systems 30that occur in higher eukaryotic cells.
In this invention, a gene coding for an insect-specific toxin is inserted into a suitable location in the viral genome. Heterologous genes inserted into AcMNPV produce proteins which are active in the infected insect cells.
6 These proteins, for the most part, undergo posttranslational processing to produce and secrete recombinant products very similar, if not identical, to. those of authentic proteins. A toxin thus expressed enhances the bioinsecticidal effect of the virus.
One such toxin is AaIT, which is produced by the venom of the North African scorpion Androctonus Australis Hector. The toxin is 70 amino 10 acids in length and binds to sodium channels in insects and causes contractile paralysis at the nanogram to microgram range in insect larvae.
Because AaIT does not bind to mammalian sodium channels, AaIT is a candidate for use as a bioinsecticide to protect crops ingested by humans.
The region upstream of the coding region of the AaIT gene includes a signal sequence which directs the secretion of AaIT from the cell.
Specifically, the signal sequence directs the toxin through the secretory pathway to the cell surface where it is secreted from the cell. During transport, enzymes cleave the signal sequence, leaving the mature AaIT.
There is a continuing need for genetically 25 engineered recombinant insect viruses which express heterologous toxins in infected hosts. Infection by these recombinant viruses increases the speed of kill when compared with the wild-type virus.
30 Summary of the Invention This invention provides for the construction of a codon optimized DNA sequence encoding the insect-specific toxin AaIT. The codon optimized sequence is then inserted into an insect 7 virus such as the baculovirus AcMNPV.
The baculovirus infects specific susceptible insect target species, resulting in the eventual death of the insect in its larval stage.
The toxin AaIT produced by a scorpion is also specific for susceptible insect target species (but not vertebrates) and causes paralysis and ultimately death of the insect.
The insertion of the gene encoding AaIT into a baculovirus results in the expression of the toxin. A susceptible insect which ingests such a modified baculovirus will cease feeding on plants due to a toxin-induced paralysis at an earlier time than an insect which ingests a wild-type baculovirus lacking an AaIT gene. The greater the reduction in time, the greater the reduction of damage to crops, because the period of larval feeding is reduced.
Thus, this invention provides a method for protecting plants from damage from insects, by delivering to the plant (through spraying or other delivery means) an expression vector incorporating this codon optimized nucleic acid sequence for producing AaIT.
The degeneracy of the genetic code permits 25 variations of the nucleotide sequence, while still producing a polypeptide having the identical amino acid sequence as the polypeptide encoded by the native DNA sequence.
The frequency of individual synonymous 30 codons for cognate amino acids varies widely from genome to genome among eucaryotes and procaryotes.
These differences in codon choice patterns appear to contribute to the overall expression levels of individual genes by modulating peptide elongation rates.
8 The invention involves the design of an AaIT gene for use in a baculovirus expression system. It is first attempted to have the preferred codon usage frequencies for this synthetic gene reflect the codon usages of genes derived from the genome of the cell/organism to be used for recombinant protein expression. However, adequate representation for both lepidopteran gene sequences and insect viral gene sequences was not available at the-time of this invention to create a reliable codon usage table, because there was DNA sequence information available from only a small number of genes.
Therefore, codon use tables are taken from a species, Drosophila melanoqaster, which has a sufficient number (at least 10) of known gene sequences. These codon use tables are used to design the codon optimized gene encoding AaIT. This methodology also permits the preservation or destruction (if desired) of restriction enzyme recognition sites. The codon use frequency for each Samino acid of AaIT reflects frequencies in Drosophila melanogaster codon use tables.
The codon optimized gene encoding AaIT of S" 25 this invention has the sequence of 210 nucleotides as follows: AAG AAG AAC GGC TAC GCA GTC GAC TCA TCC GGA AAA GCC SCCC GAG TGC CTG CTC TCG AAC TAT TGC-AAC AAT GAA TGC ACC AAG GTG CAC TAC GCT GAC AAG GGC TAC TGT TGC CTT CTG TCC TGC TAT TGC TTC GGT CTC AAC GAC GAC AAG AAA GTT CTG GAA ATC TCT GAT ACT CGC AAG AGC TAC TGT GAC ACC ACC ATC ATT AAC TAA The wild-type (native) AaIT gene sequence is as follows: AAG AAG AAT GGA TAT GCC GTC GAT AGT AGT GGT AAA GCT 9 CCT GAA TGT CTT TTG AGC AAT TAC TGT AAC AAC GAA TGC ACA AAA GTA CAT TAT GCT GAC AAA GGA TAT TGC TGC TTA CTT TCA TGT TAT TGC TTC GGT CTA AAT GAC GAT AAA AAA GTT TTG GAG ATT TCG GAC ACA AGG AAA AGT TAT TGT GAC ACC ACA ATA ATT AAT TAA The codon optimized sequence differs from that of the wild-type AaIT gene sequence in 58 out of 210 nucleotides (see Figure However, both the codon optimized and the wild-type sequences encode the identical 70 amino acid long AaIT toxin, which has the following amino acid sequence: Lys Lys Asn Gly Tyr Ala Val Asp Ser Ser Gly Lys Ala Pro Glu Cys Leu Leu Ser Asn Tyr Cys Asn Asn Glu Cys Thr Lys Val His Tyr Ala Asp Lys Gly Tyr Cys Cys Leu Leu Ser Cys Tyr Cys Phe Gly Leu Asn Asp Asp Lys Lys Val Leu Glu lie Ser Asp Thr Arg Lys Ser Tyr Cys Asp Thr Thr lie lie Asn Brief Description of the Drawings Figure 1 depicts a comparison of the nucleotide sequences of of native and codon optimized genes encoding AaIT, together with the amino acid sequence of AaIT.
Figure 2 depicts detail of the construction of the plasmid pBS Cuticle-AaIT, which contains the heterologous cuticle signal sequence and a codon optimized cDNA sequence encoding AaIT.
Figure 3 depicts detail of the construction of the plasmid pBS GIII-AaIT, which contains the native signal sequence and the native cDNA sequence encoding AaIT.
Figure 4 depicts the levels of toxinencoding RNA as a percentage of polyhedrin RNA which accumulates in Sf9 cells infected with wild-type 10 AcMNPV. A DNA probe detects the 3' untranslated region common to both toxin and polyhedrin RNAs.
The bars on the X axis are as follows: Mock (noninfected); Wild Type (wild-type AcMNPV); Es6-AaIT (AcMNPV containing esterase-6 signal sequence and codon optimized AaIT gene); ADK-AaIT (AcMNPV containing adipokinetic signal sequence and codon optimized AaIT gene); Cut-AaIT (AcMNPV containing cuticle signal sequence and codon optimized AaIT gene); pBM-AaIT (AcMNPV containing pBMHPC-12 signal sequence and codon optimized AaIT gene); Chor-AaIT (AcMNPV containing Chorion signal sequence and codon optimized AaIT gene); Apo-AaIT (AcMNPV containing apolipophorin signal sequence and codon optimized AaIT gene); Sex-AaIT (AcMNPV containing sex specific signal sequence and codon optimized AaIT gene); and grp III-AaIT (AcMNPV containing native signal sequence and native AaIT gene).
Figure 5 depicts graphs of the response time of H. virescens larvae in a viral injection assay. In Panel A, larvae receive either no virus S(negative control)(80 insects) or 100, 1000 or 1" 0,000 PFU of wild-type AcMNPV (Strain E2)(48 S- insects each). In Panel B, larvae receive either no 25 virus (negative control)(80 insects) or 100, 1000 or 10,000 PFU of AcMNPV which contains the cuticle signal sequence and a codon optimized cDNA encoding AaIT (48 insects each).
Figures 6-15 depict graphs of the oral 30 toxicity of viruses, presented as a percentage of larvae responding at various time intervals to the indicated doses of virus present in a microdrop of ingested diet. Figure 6 depicts wild-type AcMNPV :(Strain E2), which is used as a control for Figures 7-10. Figure 7 depicts an esterase-6-AaIT-virus 11 construct. Figure 8 depicts an adipokinetic hormone-AaIT-virus construct. Figure 9 depicts a cuticle-AaIT-virus construct. Figure 10 depicts the native signal-native AaIT-virus construct. Figure 11 depicts wild-type AcMNPV (Strain E2), which is used as a control for Figures 12-15. Figure 12 depicts a pBMHPC-12-AaIT-virus construct. Figure 13 depicts a chorion-AaIT-virus construct. Figure 14 depicts an apolipophorin-AaIT-virus construct.
Figure 15 depicts a sex specific-AaIT-virus construct. The constructs in Figures 7-9 and 12-15 include a codon optimized AaIT gene.
Detailed Description of the Invention The present invention provides for the construction of a codon optimized DNA sequence encoding the insect-specific toxin AaIT. This isolated nucleic acid sequence is then inserted into an expression vector which is appropriate for the host cell or organism in which the toxin is to be produced. This toxin has the same amino acid sequence as native AaIT. The DNA sequence can be inserted directly into the expression vector or can Sbe inserted with the aid of a transfer vector.
The insertion of the gene encoding AaIT into an insect virus results in the expression of the toxin, which is responsible for a reduction in the time needed for the virus to incapacitate and kill larvae. A susceptible insect which ingests S..such a modified insect virus will cease feeding on plants at an earlier time than an insect which ingests a wild-type insect virus lacking an AaIT gene. The greater the reduction in time, the greater the reduction of damage to crops, because 12 the period of larval feeding is reduced.
The degeneracy of the genetic code permits variations of the nucleotide sequence, while still producing a polypeptide having the identical amino acid sequence as the polypeptide encoded by the native DNA sequence. The procedure known as codon optimization provides one with a means of designing such an altered DNA sequence.
The design of codon optimized genes should take into account a variety of factors, including the frequency of codon usage in an organism, nearest neighbor frequencies, RNA stability, the potential for secondary structure formation, the route of synthesis and the intended future DNA manipulations of that gene.
The degeneracy of the genetic code permits the same amino acid sequence to be encoded and translated in many different ways. For example, leucine, serine and arginine are each encoded by six different codons, while valine, proline, threonine, alanine and glycine are each encoded by four different codons.
However, the frequency of use of such synonymous codons varies from genome to genome among 25 eucaryotes and procaryotes. For example, synonymous codon-choice patterns among mammals are very similar, while evolutionarily distant organisms such as yeast cerevisiae), bacteria (such as E. coli) and insects (such as D. melanogaster) reveal a clearly different pattern of genomic codon use frequencies (8-13).
These differences in codon-choice patterns appear to contribute to the overall expression levels of individual genes by modulating peptide elongation rates. Two lines of experimental 13 evidence support this argument. First, the rate of polypeptide synthesis depends on the character of the codons being translated, as well as the initial kinetics for transfer RNA ("tRNA") ternary complex formation (13-18). Second, cellular transfer RNA distributions tend to follow the cognate codon frequencies of the messenger RNA ("mRNA") pool (18- 21).
For these reasons, it is desirable and useful to design genes intended for insect virus expression systems where the codon frequencies reflect the cognate cellular tRNA frequencies. This is particularly desirable for expression systems like the baculovirus expression system using the polyhedrin promoter, where a single mRNA specie may utilize over one-half the cellular translation capacity. Hence, codon frequency really should reflect the cognate cellular tRNA frequencies when expressing recombinant protein at high levels.
The preferred codon usage frequencies for a synthetic gene should reflect the codon usages of nuclear genes derived from the exact (or as closely related as possible) genome of the cell/organism Sthat is intended to be used for recombinant protein 25 expression.
In the present invention, adequate representation for both lepidopteran gene sequences and insect viral gene sequences was not available to create a reliable codon usage table for these S30 initial experiments.
e For example, for the design of the AaIT gene, there was at the time of this invention DNA sequence information from only two specialized proteins: AcMNPV polyhedrin and AcMNPV plO (22,23).
Ikemura et al. have cautioned that reliable codon- 14 choice patterns require the summation of codon frequencies from ten or more genes with varying functions (10,24). This codon optimized sequence is intended to be expressed in a variety of insects, not just those infected by AcMNPV. Therefore, it is of primary importance that the codon optimization be compatible with the tRNA pool distribution in a variety of insect cells.
For this reason, an insect specie is selected which has a sufficient number of known gene sequences. Drosophila melanoqaster has codon use tables derived from 44 nuclear genes totalling 20,451 codons These codon use tables are used to design the codon optimized genes encoding signal sequences and the AaIT toxin sequence of this invention.
A gene for a full length signal peptide sequence is fused to the codon optimized AaIT toxin peptide sequence. As discussed in detail below, the signal sequence may be the AaIT signal sequence or a native or codon optimized nucleotide sequence *encoding a heterologous signal sequence.
These amino acid sequences are reverse- S translated into a DNA sequence showing all possible 25 nucleotide degeneracies (maximum ambiguity). A list of definite and potential (because of codon degeneracies) restriction enzyme recognition sites is generated. Restriction enzyme sites critical for gene synthesis as well as for the convenience of additional DNA manipulation are selected and preserved. One important advantage of assigning codons during the design of optimized genes is that restriction enzyme sites can be readily preserved or adestroyed at the convenience of one skilled in the S 35 art to facilitate gene contruction and manipulation.
15 A list recording the number of times each amino acid occurs in AaIT and each signal sequence is generated. Codons are assigned on the basis of the number of amino acid residues present in the sequence to reflect the relative frequency of Drosophila melanoqaster codon use (11).
For example, the cysteine codon frequency in Drosophila melanogaster is 76% for the sequence TGC and 24% for the sequence TGT. There are eight cysteine residues in the ADK signal-AaIT gene construct (all in the gene coding for the mature AaIT protein). Hence, six codons are allocated as TGC (75% of the residues) and two codons as TGT of the residues). Based on this distribution, each cysteine codon is then assigned an exact, unambiguous sequence. Attention is given to alternating adjacent isocodons. For example, the two adjacent cysteine residues in the AaIT peptide (amino acids 37 and 38) are assigned the sequence TGT TGC to avoid assigning two identical codon sequences sequentially.
This process is repeated for all twenty sees amino acids and the termination codon (although the I* termination codon sequence TAA is not changed by 25 this procedure). In addition, all critical restriction enzyme sites are preserved and unwanted sites are destroyed.
The codon optimized nucleic acid sequence *o of this invention is synthesized and assembled using conventional techniques. Example 2 below describes S* one such method using a series of synthetic oligonucleotide fragments which are then joined to form the complete coding sequence.
As set forth above, the complete codon optimized sequence of this invention differs from t 16 the native cDNA sequence encoding AaIT by 58 out of 210 nucleotides (see Figure However, the AaIT produced by the native cDNA and the codon optimized cDNA have identical amino acid sequences. If desired, the signal sequence for AaIT may also be codon optimized by the same procedures just described.
Once the synthetic gene containing the codon optimized nucleic acid sequence is constructed, the gene is inserted into an appropriate expression vector, by conventional techniques such as cloning into the vector after digestion with one or more appropriate restriction enzymes. Smith and Summers United States Patent 4,745,051 describes the construction of baculovirus expression vectors, which are recombinant insect viruses in which the coding sequence for a foreign gene is inserted behind a baculovirus promoter in place of the viral 20 polyhedrin gene. The polyhedrin gene is nonessential for productive viral infection between cells.
Transfer vectors are used as tools to transfer foreign genes into a viral genome.
25 Transfer vectors generally are bacterial plasmids containing sufficient viral sequences to facilitate insertion of the foreign gene into the viral genome by homologous recombination.
•Methods for constructing recombinant baculoviruses in cultured cells are set forth in M.
D. Summers and G. E. Smith, A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures, Texas Agricultural Experimental Station Bull. No. 1555 (1987) A preferred cell line is that of Sf9 cells (ATCC accession number 17 CRL1711), which are derivatives of the cell line designated Spodoptera fruqiperda 21 (Sf21). Other insect cell lines that are adequate for propagation of a desirable insect virus include those derived from Trichoplusia ni (TN368), the silkworm Bombyx mori (BM) and Helicoverpa zea (BCIRL-Hz-Aml, BCIRL- Hz-Am3).
Suitable insect viruses include those listed above in the Background of the Invention. A preferred insect virus is the baculovirus AcMNPV. A particular strain of AcMNPV designated E2 is used in the Examples. Those of skill in the art will recognize that other baculovirus strains may also be used. These include Trichoplusia ni MNPV, Rachiplusia ou MNPV, Galleria mallonella MNPV, Spodoptera fruqiperda NPV and plaque-purified strains such as the M3, R9, Sl and S3 strains of AcMNPV isolated and characterized in Smith, G.E., and Summers, J. Virol., 33, 311-319 (1980) 20 as well as Bombvx mori NPV. See also Smith, and Summers, Virol., 89, 517-527 (1978) S(27).
As described above, the expression of AaIT by an insect virus reduces the time needed to 25 incapacitate a larva. In turn, the maturation and secretion of functional toxin is facilitated by a signal peptide.
S" Signal sequences are required for a complex series of post-translational processing steps which result in secretion of a protein. If an intact signal sequence is present, the protein being expressed enters the lumen of the rough endoplasmic reticulum and is then transported through the Golgi apparatus to secretory vesicles and is finally transported out of the cell. Generally, the signal 18 sequence immediately follows the initiation codon and encodes a signal peptide at the amino-terminal end of the protein to be secreted. In most cases, the signal sequence is cleaved off by a specific protease, called a signal peptidase. Preferred signal sequences improve the processing and export efficiency of recombinant protein expression using viral expression vectors. Optimized expression of the toxin using an appropriate heterologous signal sequence achieves more rapid lethality than wildtype insect virus.
Summers United States Patent 5,155,037 (28) describes the use of insect signal sequences such as adipokinetic hormone and cuticle in a Lepidopteran insect cell transformed or transfected with a DNA vector, where said signal directs the secretion of a heterologous protein from the insect cell. The only foreign proteins disclosed are CD4, interleukin-2 and beta-interferon. All of these 20 proteins are mammalian proteins; none is an insect toxin. Prior to United States Patent 5,155,037, the only method of achieving secretion of a foreign protein in insect cells is by using the foreign gene's native signal peptide. Because the foreign 25 genes are usually from non-insects, their signals may be poorly recognized by insect cells, resulting in suboptimal levels of expression. The signal sequence is generally coded by a DNA sequence immediately following to the translation start site of the foreign gene. Proteins secreted from cells are synthesized as precursor molecules containing hydrophobic N-terminal signal peptides.
A secretory signal sequence contains three regions: A basic N-terminal region (n-region); a hydrophobic region (h-region); and a more 19 polar C-terminal region (c-region) Cleavage of the signal sequence from the mature protein once export is under way appears to be dependent upon structures in the n- and h- regions; however, positions -3 and -1 relative to the cleavage site (in the c- region) have been suggested to be the most important The residue in position -1 should be small (alanine, serine, glycine, cysteine, threonine or glutamine), while the residue in position -3 should not be aromatic (phenylalanine, histidine, tyrosine or tryptophan), charged (asparagine, glutamic acid, lysine or arginine) or large and polar (asparagine or glutamine), with proline being absent from the region -3 to Some exceptions to these parameters are permitted (29).
This -1 rule is 75-80% predictive of the cleavage site in mammalian systems but has not been confirmed in insect systems.
Summers United States Patent 5,155,037 20 (28) describes the sequence encoding the Lepidopteran (Manduca sexta) adipokinetic hormone signal peptide. This is a short signal peptide (19 amino acids) for a blocked neuropeptide that regulates energy substrate mobilization and 25 metabolism in insects. Figure 2B of the patent depicts the nucleotide and amino acid sequences of the signal peptide.
The patent also describes the sequence o*"o encoding Drosophila melanoqaster cuticle signal peptide. Figure 2A of the patent depicts the nucleotide and amino acid sequences of the cuticle gene CP1 leader peptide. The nucleotide sequence codes for a 16 amino acid signal peptide.
In an effort to identify heterologous signal sequences useful with the codon optimized 20 AaIT gene, eight constructs with heterologous signal sequences are prepared by Applicants. The DNA sequences encoding these signal sequences can be either the native DNA sequences encoding the signal sequences or the codon optimized DNA sequences encoding those signal sequences.
These signal sequences are then combined with the codon optimized AaIT gene described previously in Bluescript plasmids (Stratagene, LaJolla, CA). Each such gene is inserted into a baculovirus transfer vector and then moved into the AcMNPV genome by homologous DNA recombination in cultured cells The heterologous signal sequences are as follows: Interleukin-2, Esterase- 6, Adipokinetic hormone, Cuticle, pBMHPC-12, Chorion, Apolipophorin, and Sex Specific.
Interleukin-2 is a human signal sequence (for a T-cell growth factor) whose use with AaIT has previously been described The adipokinetic 20 hormone signal sequence (for a neuropeptide) is from Manduca sexta and fits the -1 rule (29) well.
The chorion signal sequence from Bombyx mori (for an eggshell structural protein) and the cuticle signal sequence of Drosophila melanocaster (for an 25 exoskeletal protein) both secrete a large quantity of their associated mature proteins. The apolipophorin signal sequence from Manduca sexta (for a plasma lipid transport protein), the sex specific signal sequence of Bombvx mori (for a major adult plasma storage protein) and the pBMHPC-12 signal sequence from Bombvx mori (for a 30 kD larval plasma lipoprotein) all are selected because they are found in fat body cells and and each secrete a hemolymph protein. Finally, the esterase-6 signal sequence is used for the secretion of a serine 21 hydrolase from Drosophila melanoqaster. Each of these signal sequences except apoliphophorin complies with the -1 rule (29) for predicting the cleavage site.
The cDNA encoding each signal sequence can have either its native sequence or a codon optimized sequence generated as described above. Specific codon optimized signal sequences are constructed as described in Example 2 below.
The codon optimized signal sequences differ from the native sequences as follows: pBMHPC-12 7 of 48 nucleotides compare the codon optimized sequence: ATG AAA CTC CTG GTC GTG TTC GCC ATG TGC GTG CCC GCT GCC AGC GCT with the native sequence: ATG AAA CTT CTC GTT GTG TTC GCA ATG TGC GTG CCT GCC GCC AGC GCC adipokinetic hormone 6 of 57 nucleotides compare the codon optimized sequence: ATG TAC AAA CTG ACC GTC TTC CTG ATG TTC ATC GCC TTC GTG ATT ATC GCT GAG GCC with the native sequence: ATG TAC AAG CTC ACA GTC TTC CTG ATG TTC ATC GCT TTC 25 GTC ATC ATC GCT GAG GCC apolipophorin 14 of 69 nucleotides compare the codon optimized sequence: ATG GCC GCT AAA TTC GTC GTG GTT CTG GCC GCT TGC GTC S* GCC CTG AGC CAC TCG GCT ATG GTG CGC CGC the native sequence: :ATG GCA GCC AAG TTC GTC GTG GTT CTC GCC GCG TGC GTG GCC CTC TCG CAC AGC GCG ATG GTG CGC CGC chorion 10 of 63 nucleotides compare the codon optimized sequence: TTC ACC TTC GCT ATT CTG CTC CTG TGC GTG CAA GGC 22 TGC CTG ATC CAG AAT GTT TAC GGA with the native sequence: ATG TTT ACC TTC GCT ATT CTC CTT CTC TGC GTT CAG GGT TGC CTG ATC CAA AAT GTG TAC GGT cuticle 6 of 48 nucleotides compare the codon optimized sequence: ATG TTC AAG TTC GTG ATG ATC TGC GCC GTC CTC GGC CTG GCT GTG GCC with the native sequence: ATG TTC AAG TTT GTC ATG ATC TGC GCA GTT TTG GGC CTG GCG GTG GCC esterase-6 15 of 63 nucleotides compare the codon optimized sequence: ATG AAC TAC GTC GGG CTG GGC CTC ATC ATT GTG CTG TCG TGC TTG TGG CTG GGG AGC AAT GCT with the native sequence: ATG AAC TAC GTG GGA CTG GGA CTT ATC ATT GTG CTG AGC TGC CTT TGG CTC GGT TCG AAC GCG ~..:sex-specific 15 of 45 nucleotides compare the codon optimized sequence: ATG CGC GTC CTG GTG CTG TTG GCC TGC CTG GCA GCC GCT .4...AGC GCT with the native sequence: ATG AGG GTT CTA GTA CTA CTG GCC TGC TTG GCC GCG GCG TCA GCC However, the amino acids of the signal sequences encoded by the differing nucleic acid sequences are identical for both the codon optimized and native sequences.
An example of a codon optimized DNA sequence encoding a heterologous cuticle signal sequence joined to a codon optimized DNA sequence encoding AaIT and inserted into a baculovirus transfer vector is the transfer vector designated pACOO55.1 (see Examples 1, 2 and 4 below). Samples 23 of an E. coli strain HB101 harboring this transfer vector pAC0055.1 were deposited by applicants on December 17, 1992 with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852, and have been assigned ATCC accession number 69166. Using this deposited material, one of ordinary skill in the art can substitute a different signal sequence for the cuticle sequence contained in that plasmid.
Specifically, the first step is to construct a synthetic double stranded DNA fragment which has the following features: a 5' terminal Bam HI-compatible cohesive end; (ii) a sequence encoding the ATG start codon and amino acid sequence of the new signal peptide; and (iii) a sequence encompassing the first 19 nucleotides in the top strand of the codon optimized AaIT gene and the first 23 nucleotides in the bottom strand. The 3' terminus of such a fragment contains a Sal I- 20 compatible cohesive end. Substitution of this fragment for the corresponding Bam HI/Sal I fragment of pAC0055.1 is achieved by joining the following three fragments in the presence of DNA ligase: (1) the Bam HI/Sal I synthetic fragment described above; 25 a Sal I/Kpn I fragment extending from the Sal I site at codons 6-7 in the codon optimized AaIT toxin gene to the Kpn I site in the 3' flanking polyhedrin gene sequence; and the largest Kpn I/Bam HI fragment contained in pAC0055.1. This fragment, which is derived from pVL985 contains the pUC8 cloning vector and AcMNPV sequences which flank the 5' and 3' termini of the polyhedrin gene. Those skilled in the art will recognize that the resulting construct differs from pAC0055.1 only in the nature of the signal peptide.
24 Once recombinant viruses are prepared containing the codon optimized gene (see discussion above and Examples 1, 2, 4 and 5 below), they are tested to confirm the presence of the codon optimized AaIT gene. Because the codon optimized gene replaces the baculovirus polyhedrin gene, the recombinant viruses which carry the toxin gene are unable to form polyhedra and thus produce occlusionnegative plaques. Plaque purification is used to isolate recombinant viruses containing the AaIT gene from the transfection supernatant by the method of Summers and Smith (25) (see Example Next, virus infected cells are assayed by dot blot hybridization for nucleic acids that hybridize to a radiolabelled DNA probe specific for the AaIT gene. Radioactivity is detected by autoradiography; a positive result confirms the presence of the AaIT gene in a virus isolate (see Example 6).
20 Methods similar to those described in Examples 1, 2, 4 and 5 below are used to construct a baculovirus transfer vector containing the native AaIT gene and the native nucleic acid sequence encoding the native AaIT signal sequence, and then 25 to prepare recombinant virus therefrom (see Examples 3-5 below). Polymerase chain reaction is used to verify that the recombinant viruses contain an insert of the correct size containing the AaIT gene (see Example 7 below). The recombinant viruses containing the native AaIT gene are used as positive controls in assays for the biological activity of S. recombinant viruses containing the codon optimized AaIT gene with heterologous signal sequences.
Expression of the AaIT gene in insect cells infected with either the codon optimized or 25 native AaIT-viruses is estimated by Northern blot analysis of total cellular RNA isolated from virusinfected cells (see Example 8 below). Analysis shows high levels of toxin-encoding RNA 24 hours post-infection (see Example 8).
As mentioned above, the baculoviruses infect a wide range of insects, but are not harmful to mammals. All species of insects examined are susceptible to paralysis caused by AaIT; however, mammals are not adversely affected by the toxin.
The comparative biological activity of a wild-type baculovirus, a virus containing the native AaIT gene, and a virus containing the codon optimized AaIT gene (which may also contain a heterologous signal sequence) is assayed by two types of in vivo tests with insect larvae: an injection assay and a feeding assay.
In a preliminary assay, the culture medium and cell pellets (resuspended in buffer solution) 20 obtained during the preparation of codon optimized AaIT-viral stocks are injected into Musca domestica (common house fly) larvae to determine whether those samples contain a detectable amount of biologically active AaIT.
25 Larvae are examined five seconds after injection for evidence of involuntary contraction of body segments. Results from the assay (see Table in Example 9 below) show that biologically active AaIT is detected in the cultured cells infected with 13 of 14 codon optimized AaIT-virus isolates with heterologous signal sequences (esterase-6, adipokinetic hormone and cuticle). The negative results are expected with the IL2-AaIT-virus constructs due to the presence of a frame shift mutation in the toxin gene coding region. The lack 26 of detectable AaIT activity in any of the cell culture supernatants indicates that the level of biologically active secreted toxin is less than about 0.2 gg/ml.
A dose-response injection assay demonstrates that the insertion of the codon optimized AaIT gene enhances the performance of a baculovirus by reducing the time needed to kill a target insect species. As shown in Example 10 below and Figure 5, budded virus prepared from the codon optimized Cuticle-AaIT-AcMNPV construct and from the wild-type E2 strain of AcMNPV without the AaIT gene are injected into separate groups of mid-fourth instar larvae at doses of 102, 103 and 104 PFU per larva.
At each of the doses tested,the Cuticle- AaIT-AcMNPV kills its host faster than the wild-type AcMNPV. At 104 PFU, the LTS, for the wild-type virus .is approximately 97 hours, whereas the corresponding 20 LTS, for the Cuticle-AaIT AcMNPV is 67 hours. This result shows that insertion of the AaIT gene and the *..cuticle signal sequence into AcMNPV accelerates the speed of kill through the expression of biologically active toxin.
The injection assay protocol is repeated using older larvae (early fifth instar) with seven different codon optimized heterologous signal-AaIT- AcMNPV constructs, a native AaIT signal-native AaIT gene-AcMNPV construct and a wild-type E2 strain of AcMNPV without the AaIT gene. A dosage of 104 PFU of budded virus of each construct is injected into separate groups of larvae.
As described in Example 11 below, each of the codon optimized heterologous signal-AaIT-AcMNPV constructs (as well as the native AaIT signal-native 27 AaIT gene-AcMNPV construct) kills its host faster than the wild-type AcMNPV. The LTso for the wildtype virus is approximately 126 hours, whereas the corresponding LT 5 for the seven heterologous signal- AaIT-AcMNPV constructs range from approximately 68- 89 hours and the native AaIT-AcMNPV construct has an LTS, of approximately 74 hours. These results confirm the results of Example 10 that insertion of the AaIT gene and a heterologous signal sequence into AcMNPV accelerates the speed of kill through the expression of biologically active toxin.
In order to test the oral toxicity of these recombinant viruses, which are defective for the production of polyhedrin, polyhedra containing a mixture of wild-type and recombinant virions are prepared by co-infecting cells in culture with the recombinant AaIT-virus and a wild-type helper virus (such as the E2 strain of AcMNPV). This approach is made possible because one polyhedron (occlusion 20 body) contains several hundred virions.
Accordingly, host cells are co-infected with various amounts of the recombinant AaIT-virus, as well as a wild-type virus. The resulting infected cells have polyhedra containing a mixture 25 of wild-type and recombinant virions. As seen in Example 12 below, when the MOI of the wild-type virus is at least 2 PFU per cell, as the MOI of the recombinant virus increases, the percent of cells with viral occlusions and the average number of polyhedra per cell decrease significantly.
Therefore, further co-occlusion studies are conducted with the occlusion-negative recombinant virus and the wild-type virus, each at an MOI of 3.
This allows effective representation of the recombinant virions in the polyhedra at an 28 acceptable level of polyhedron production.
Finally, an oral toxicity assay is conducted by feeding larvae a microdrop of insect diet containing a desired amount of PIBs. With the exception of the wild-type virus, each PIB contains a mixture of wild-type and recombinant virions. The recombinant virions may encode either the native AaIT gene (and native signal sequence), or the codon optimized gene linked to a heterologous signal sequence.
Larvae are then monitored for paralysis and death. The results of the assay are set forth in Example 13 and Figures 6-15.
All but one of the recombinant viruses demonstrate an earlier onset of morbidity than the wild-type AcMNPV (which lacks the AaIT gene). The exception is the AcMNPV construct containing the pBMHPC-12 signal sequence linked to the codon :optimized sequence encoding AaIT, which performs 20 approximately the same as the wild-type AcMNPV. The recombinant viruses exhibit a characteristic S. paralytic response which is easily distinguished from the pathogenesis caused by the wild-type virus.
The actual ratio of wild-type to recombinant virus 25 in the polyhedra and in the infected insects is not '.analyzed.
In order that this invention may be better understood, the following examples are set forth.
i The examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention.
Examples Standard molecular biology techniques are 29 utilized according to the protocols described in Sambrook et al. (32).
Example 1 Determination of a Codon Optimized cDNA Sequence Encoding AaIT The design of a codon optimized gene for AaIT begins with an attempt to reflect the codon usages of nuclear genes derived from the exact (or as closely related as possible) genome of the cell/organism that is intended to be used for recombinant protein expression. Here, however, adequate representation for both lepidopteran and baculoviral gene sequences was not available to create a reliable codon usage table for these initial experiments.
Ikemura et al. have cautioned that reliable codon-choice patterns require the summation of codon frequencies from ten or more genes with 20 varying functions (10,24). However, at the time of this invention, there was DNA sequence information from only two specialized proteins: AcMNPV polyhedrin and AcMNPV plO (22,23).
S" For this reason, Drosophila melanogaster is selected because its codon use tables are derived from 44 nuclear genes totalling 20,451 codons (11).
These codon use tables are used to design the codon optimized genes encoding signal sequences and the AaIT toxin sequence of this invention.
30 Each full length signal peptide sequence is fused to the AaIT toxin peptide sequence. These amino acid sequences are reverse-translated into a DNA sequence showing all possible nucleotide 30 degeneracies (maximum ambiguity) using IntelliGenetics Suite M software (version 1988; Palo Alto, CA). IntelliGenetics Suite T software is used for all computer-assisted nucleic acid sequence analysis.
A list of definite and potential (because of codon degeneracies) restriction enzyme recognition sites is generated. Restriction enzyme sites critical for gene synthesis as well as for the convenience of additional DNA manipulation are selected and preserved. For example, Bam HI and Ava I restriction enzyme sites are required for gene synthesis using Bluescript SK/KS vectors (Stratagene, LaJolla, CA). Sal I and Apa I restriction sites are desirable to permit flexibility for additional gene manipulation.
Using IntelliGenetics Suite T software, a list recording the number of times each amino acid occurs in AaIT and each signal sequence is 20 generated. Codons are assigned on the basis of the number of amino acid residues present in the sequence to reflect the relative frequency of Drosophila melanogaster codon use (11).
For example, the cysteine codon frequency 25 in Drosophila melanogaster is 76% for the sequence TGC and 24% for the sequence TGT. There are eight cysteine residues in the ADK signal-AaIT gene construct (all in the gene coding for the mature AaIT protein). Hence, six codons are allocated as TGC (75% of the residues) and two codons as TGT a: of the residues). Based on this distribution, each cysteine codon is then assigned an exact, unambiguous sequence. Attention is given to alternating adjacent isocodons. For example, the two adjacent cysteine residues in the AaIT peptide 31 (amino acids 37 and 38) are assigned the sequence TGT TGC to avoid assigning two identical codon sequnces sequentially.
This process is repeated for all twenty amino acids and the termination codon (although the termination codon sequence TAA is not changed by this procedure). In addition, all critical restriction enzyme sites are preserved and unwanted sites are destroyed.
Flanking DNA sequences for the plasmid vectors as well as the transfer vectors are fused to the completed gene sequences to confirm that there are no undesirable restriction enzyme sites at the splice-junction boundaries.
Example 2 Construction of Gene Cassettes Containing an Heterologous Signal Sequence Plus the Codon Optimized cDNA Sequence Encoding AaIT 999 Eight heterologous signal sequence-codon 20 optimized AaIT toxin gene cassettes are synthesized and assembled in two pieces: A fragment, unique for each construct, consisting of DNA coding for one of eight heterologous signal sequences, plus the amino terminal portion of the toxin coding region (common to all constructs), and an fragment, which is the same for each construct and encodes the remainder of the toxin coding region.
Each of fragments A and B is made by annealing a pair of oligomers containing a 15 bp overlap purchased from New England Biolabs (Beverly, MA). Sequenase T 2.0, a DNA polymerase (United States Biochemical Corporation, Cleveland, OH), is used to complete the double stranded molecule, which 32 contains the heterologous signal sequence plus the codon optimized cDNA sequence encoding AaIT. The following is a list of the oligomers used in the construction of these eight constructs: Fragment A El 5' AGCCCCCGAG TGCCTGCTCT CGAACTATTG CAACAATGAA TGCACCAAGG TGCACTACGC TGACAAGGGC TACTGTTGCC TTCTGTCCTG CTATTGCTTC 3' E2 5' CTGTAGGTAC CGGATCCTTA GTTAATGATG GTGGTGTCAC AGTAGCTCTT GCGAGTATCA GAGATTTCCA GAACTTTCTT GTCGTCGTTG AGACCGAAGC AATAGCAGGA 3' Fragments Bl-8 Common AGGCACTCGG GGGCTTTTCC GGATGAGGTC 054 *GACTGCGTAG CCGTTCTTCT T 3' IL-2 CCCCCCGGAT CCATGTACCG CATGCAGCTG CTCTCCTGCA TCGCCCTGTC GCTGGCTCTG GTGACCAATA GCAAGAAGAA CGGCTAC 3'
ADK
CCCCCCGGAT CCATGTACAA ACTGACCGTC :TTCCTGATGT TCATCGCCTT CGTGATTATC GCTGAGGCCA AGAAGAACGG CTAC 3' Chori on CCCCCCGGAT CCATGTTCAC CTTCGCTATT 33 CTGCTCCTGT GCGTGCAAGG CTGCCTGATC CAGAATGTTT ACGGAAAGAA GAACGGCTAC Esterase-6 CCCCCCGGAT CCATGAkCTA CGTCGGGCTG GGCCTCATCA TTGTGCTGTC GTGCTTGTGG CTGGGGAGCA ATGCTAAGALA GAACGGCTAC Apolipophorin
CCCCCCGGAT
GTGGTTCTGG
CACTCGGCTA
GGCTAC 3' Sex-Specific
CCCCCCGGAT
TTGGCCTGCC
AAGAACGGCT
CCATGGCCGC TAAATTCGTC CCGCTTGCGT CGCCCTGAGC TGGTGCGCCG CAAGAAGAAC CCATGCGCGT CCTGGTGCTG TGGCAGCCGC TAGCGCTAAG AC 3' 0@ 0 *0 S.0 *0 So.
s ee Cuticle
CCCCCCGGAT
ATCTGCGCCG
AAGAAGAACG
CCATGTTCAA GTTCGTGATG TCCTCGGCCT GGCTGTGGCC GCTAC 3' 20 pBMHPC-12 5' CCCCCCGGAT CCATGAAkCT CCTGGTCGTG TTCGCCATGT GCGTGCCCGC TGCCAGCGCT AkGAAGAACG GCTAC 3' Figure 2 depicts the construction strategy for the AaIT gene cassette which contains the Drosophila melanocraster cuticle signal sequence.
The remaining seven heterologous signal sequence- AaIT gene cassettes are constructed in the same way using the specific oligo for the signal sequence as 34 indicated above.
In the first step, the signal sequencespecific oligo for the B fragment and the common B oligo are annealed and the single stranded regions are filled in using Sequenase™ 2.0. Each signal sequence-specific oligo consists of an identical 12 nucleotide upstream noncoding region containing the Bam HI site required for cloning, the coding region for the signal sequence, and the first nucleotides encoding the first five amino-terminal amino acids of AaIT. This short piece of double stranded DNA is digested with Bam HI and Ava I and subcloned into pBluescript SK+ (Stratagene, LaJolla, CA) which had been digested with Xma I and Bam HI.
15 Positive subclones are verified by the presence of a Pvu II fragment larger than the 445 bp fragment present in pBluescript SK+ alone. There is a single base pair mismatch between the overhangs for the Ava I and Xma I sites. Clones which have corrected this mismatch to regenerate the Aval site and lose the Xma I site are selected by the appropriate restriction enzyme digestions. In Figure 2, the resulting plasmid is designated pBS Cuticle B7.
To construct the A fragment encoding the 25 bulk of the AaIT coding region, oligos El and E2 are annealed and Sequenase M 2.0 is used to fill in the single stranded regions. This results in a double stranded molecule which contains an Ava I site at the 5' terminus and nested Bam HI and Asp 718 sites following the 3' end of the toxin coding region.
The Bam HI and Asp 718 sites are introduced in order to facilitate cloning. Fragment A is then digested with Ava I and Asp 718. The fragment B-containing plasmid, pBS Cuticle B7, is also digested with Ava I and Asp 718 and Fragment A is subcloned into the *3 ii 35 digested plasmid. In the case of Figure 2, the resulting plasmid is designated pBS Cuticle-AaIT.
Fragments A and B are joined at a unique Ava I site which is engineered into the AaIT sequence just for this purpose. After the ligation of fragment A into the fragment B-containing plasmid, the ligated DNA is used to transform competent DHa E. coli.
Minipreps of plasmid DNA are prepared from the resulting bacterial colonies. Restriction enzyme analysis is used to determine which colonies contain the desired recombinant DNA. Further restriction enzyme analysis, followed by DNA sequencing, is used to confirm the integrity of the eight plasmids containing the codon optimized cDNA encoding AaIT.
1. 5 Example 3 Construction of Gene Cassette Containing the Native cDNA Sequence Encoding AaIT A gene cassette containing the native cDNA sequence encoding AaIT is constructed in two pieces, but in a manner different from the construction of the codon optimized genes of Example 2. Instead of using long oligos which have only a short region of overlap to construct the gene, sets of oligos which S. completely overlap are used. A second difference in 25 the manner of construction is necessitated because the native DNA sequences for both the AaIT signal sequence and coding region are used. No artificial restriction enzyme sites are engineered into the DNA sequence. Therefore, a different method of joining the signal sequence and coding region of the AaIT gene is required. In this method, asymmetrically cutting restriction enzymes are used to allow 36 functionally separate regions of the gene to be neatly fused to each other. This allows one to mix and match premade regions in any future constructions. The sequences of the oligomers numibered 1-10 used for the construction of the native AaIT gene are provided in the list below: Oligo 1 GATCCGATGA AATTTCTCCT ATTGTTTCTC GTAGTCCTTC CAATAATGGG GGTGCTTGGC Oligo 2 GCCAAGCACC CCCATTATTG GAAGGACTAC GAGAAACAAT AGGAGAAATT TCATCG Oligo 3 AAGAAGAATG GATATGCCGT CGATAGTAGT
GGTAAAGCTC-
Oligo 4 CTCAAAAGAC ATTCAGGAGC TTTACCACTA ':CTATCGACGG CATATCCATT CTTCTT .:Oligo CTGAATGTCT TTTGAGCAAT TACTGTAACA ACGAATGCAC AAAAGTACAT TATGCT 0Oligo 6 CAGCAATATC CTTTGTCAGC ATAATGTACT TTTGTGCATT CGTTGTTACA GTAATTG 2 5 Oligo 7 GACAAAGGAT ATTGCTGCTT ACTTTCATGT TATTGCTTCG GTCTAAATGA CGATAAAAAA
GTTTTG
37 Oligo 8 CTTGTGTCCG AAATCTCCAA AACTTTTTTA TCGTCATTTA GACCGAAGCA ATAACATGAA
AGTAAG
Oligo 9 GAGATTTCGG ACACAAGGAA AAGTTATTGT GACACCACAA TAATTAATTA AG Oligo AATTCTTAAT TAATTATTGT GGTGTCACAA
TAACTTTTC
In order to facilitate the cloning of the native AaIT toxin gene cassette, a modified Bluescript SK plasmid is generated. This vector designated pBS SK Bsm I has a Bgl II linker 15 (CAGATCTG) inserted into the Nae I site located at 330bp on the Bluescript map. This linker insertion destroys the Nae I site. In addition this vector contains a modified polylinker as shown at the top in Figure 3. This modified plasmid is designated pBS SK Bsm I. This polylinker contains a Nae I site located adjacent to a Bsm I site, such that any sequence cloned into the Nae I site can be cleanly excised as a blunt-ended molecule by using the Bsm I restriction enzyme followed by filling in of the 25 sticky end with the Klenow fragment of DNA polymerase I (Gibco/BRL, Gaithersburg, MD).
To construct the native signal sequence portion of the cassette, oligos 1 and 2 are annealed. When these two oligos are properly annealed, they contain a blunt 3' end and a Bam HI sticky end at the 5' terminus. The plasmid pBS SK Bsm I is digested with Bam HI and Nae I. The 38 annealed oligos are then ligated to the digested plasmid. The resulting plasmid subclone is designated pBS GIII sig.
The coding region of the AaIT toxin is constructed as two pieces of DNA. The 5' ends of oligos 4, 5, 8 and 9 are phosphorylated using T4 kinase. Oligos 3, 6, 7 and 10 are left without a terminal phosphate. Two annealing reactions, followed by a ligation reaction using T4 DNA ligase (New England Biolabs, Beverly, MA) are carried out.
Oligos 3, 4, 5, and 6, which encode the amino terminal portion of the AaIT toxin, are annealed and ligated as shown in Figure 3. Oligos 7, 8, 9 and which encode the carboxy terminus of the AaIT 15 toxin, are annealed and ligated as shown in Figure 3.
These two oligo fragments are purified by electrophoresis on a 2.5% low melt agarose gel (Bio- Rad, Richmond, CA) containing TAE (40 mM Trisacetate, pH 7.8, 1 mM EDTA). When the fragments are sufficiently separated from contaminating fragments, they are cut out as gel slices and placed in individual tubes. The fragments are purified by phenol extraction as described in Sambrook et al.
25 (32) with the following modifications: Sodium chloride is added to the gel slices to a final concentration of 1.5 M prior to heating. No further addition of salt is required in the subsequent steps. Only two phenol extractions are performed on the liquified and diluted gel slice prior to the ethanol precipitation.
The plasmid pBS GilI sig is digested with Bsm I and the sticky end is filled in and blunted with the Klenow fragment of DNA polymerase I (Gibco/BRL). As described above, this results in 39 opening the plasmid at the last base pair of the signal sequence. The plasmid is then further digested with Eco RI. A three way ligation is then set up between the gel purified oligo fragments and the digested plasmid. Positive subclones are verified by restriction enzyme analysis, followed by DNA sequencing. One positive clone designated pBS GIII-AaIT contains the native signal sequence and full length native coding region of AaIT (Figure 3).
Example 4 Insertion of AaIT Gene Constructs into Baculovirus Transfer Vectors The heterologous signal sequence-codon optimized AaIT gene cassettes of Example 2 are 15 isolated as Bam HI fragments from the pBS signal- AaIT clones (see pBS Cuticle-AaIT example in Figure 2. These Bam HI fragments are subcloned into the pVL 985 baculovirus transfer vector DNA (31) which had been digested with Bam HI. Restriction enzyme 20 analysis followed by sequencing of the insert is used to confirm the correct orientation and integrity of the pVL heterologous signal sequencecodon optimized AaIT clones.
For example, the plasmid pBS Cuticle-AaIT 25 is subcloned into the pVL baculovirus transfer vector to yield the plasmid designated pAC0055.1.
The native AaIT gene cassette of Example 3 is isolated as a Bam HI to Eco RI fragment from the pBS GIII-AaIT clone (see Figure These Bam HI to Eco RI fragments are subcloned into pVL 1393 baculovirus transfer vector DNA (33) which had been digested with Bam HI and Eco RI. Restriction enzyme analysis followed by sequencing of-the insert is 40 used to confirm the integrity of the pVL native AaIT clones.
Example Generation of Recombinant Viruses Encoding AaIT Recombinant viruses containing the native and codon optimized AaIT genes under the control of the AcMNPV polyhedrin promoter are generated by homologous DNA recombination in cultured Sf9 cells, as described by M. D. Summers and G. E. Smith Sf9 cells (ATCC accession number CRL1711) are derivatives of the cell line designated Spodoptera fruqiperda 21 (Sf21).
In this procedure, 2.0 x 106 Sf9 cells are seeded in a 60 mm culture dish in 5 ml of 15 supplemented TNM-FH medium (Grace's insect medium (34) supplemented with 0.33% TC lactalbumin hydrolysate (Difco, Detroit, MI) and 0.33% TC yeastolate (Difco)), 10% fetal bovine serum, 0.1% Pluronic TM F-68 (Gibco/BRL)). Once the cells are 20 firmly attached (2-16 hours), the medium is removed and replaced with 0.75 ml of Grace's insect medium supplemented with 10% fetal bovine serum. One microgram of AcMNPV (E2 strain) DNA is mixed with 2 ig of AaIT-transfer vector DNA from Example 4 in 25 0.75 ml of transfection buffer (25 mM HEPES, pH 7.05, 140 mM NaCl, 125 mM CaCl 2 and added dropwise to the cells. The cells are then incubated at 27 0
C
for 4 hours. At the end of the incubation period, the transfection medium is removed and the cells are 30 washed once with TNM-FH, fed again with 5 ml of supplemented TNM-FH, and placed in a 27°C incubator.
After five days, the medium is removed from the cells, clarified by centrifugation for 10 minutes at trl 41 2000 rpm in a Beckman GPR centrifuge, and stored at 4 0 C. This constitutes the primary transfection supernatant.
Because the native and codon optimized AaIT genes replace the AcMNPV polyhedrin gene, the recombinant viruses which carry these toxin genes are unable to form polyhedra and, therefore, give rise to occlusion-negative plaques. Using this phenotype as a basis for identification, recombinant viruses containing the AaIT genes are isolated from the primary transfection supernatant by three rounds of plaque purification, using the plaque assay method of M. D. Summers and G. E. Smith In this procedure, 1.5-2.0 x 106 Sf9 cells 15 are seeded into a 60 mm culture in supplemented TNM- FH. After the cells attach (2-16 hours), the medium is removed and replaced with 1 ml of supplemented TNM-FH containing 0.001-0.1% primary transfection 9.
supernatant. The virus is allowed to adsorb to the cells for 1-2 hours at 27°C, after which it is removed and replaced with 4 ml of molten (39*C) supplemented TNM-FH containing antibiotics and low gelling temperature agarose. Once the agarose gels, the cells are transferred to an humidified 25 27°C incubator for 4-6 days. Occlusion-negative plaques are then identified by visual inspection under a stereo microscope and an agarose plug overlying each desired plaque is picked and diluted into 1 ml of supplemented TNM-FH.
The plaque purification procedure is repeated two additional times using 1-10% of the total virus recovered from each plaque. At the end of the third round, all of the virus recovered from a single plaque 1 ml) is added to 2 x 106 Sf9 cells seeded in a 25 cm 2 flask and the flask is 42 incubated at 27*C for 1-2 hours. The virus is then removed and replaced with 3 ml of supplemented TNM- FH, and the flask is returned to the incubator. At the end of 5 days, the supernatant, which is designated as the passage 1 or "P1" virus stock, is clarified by centrifugation for 10 minutes at 2000 rpm in a Beckman GPR centrifuge. Archive samples of the P1 stock are kept at -150 0 C, and the remainder of the virus is stored at 4 0
C.
Confirmation that the occlusion-negative viruses contain the desired AaIT gene is achieved by dot blot hybridization for the codon optimized AaITviruses (Example 6 below) and by polymerase chain reaction (PCR) for the native AaIT-virus (Example 7 15 below).
*.e Example 6 Confirmation of Recombinant Viruses By Dot Blot Hybridization To confirm the presence of the codon optimized AaIT gene in occlusion-negative viruses, virus-infected Sf9 cells from Example 5 are assayed by dot blot hybridization for nucleic acids that hybridize to a radiolabelled DNA probe specific for the AaIT gene. For this method, the cell pellets 25 obtained during clarification of the viral P1 stocks •are each resuspended in 1 ml Dulbecco's Phosphate Buffered Saline (D-PBS) and 100 gl aliquots are removed for hybridization. The cells are pelleted in an Eppendorf centrifuge at maximum speed for seconds and then solubilized in 0.5 ml 0.5 M NaOH.
After 10 minutes at room temperature, each sample is neutralized with 50 pl of 10 M NH 4 OH. With the aid of a 96 well dot blot apparatus, 10 to 100 Al of the 43 solubilized cell pellet is passed through a 3 mm diameter circle on a nitrocellulose membrane (Schleicher and Schuell BA85, (Keene, NH)) equilibrated with 1 M NH 4 OH, 0.02 M NaOH. The wells of the blot apparatus are then washed with 0.5 ml 1 M NH 4 OH, 0.02 M NaOH. The filter is removed from the apparatus, rinsed with 5 x SSPE (0.9 M NaC1, 50 mM NaH 2
PO
4 16.25 mM NaOH, 5 mM EDTA), and the nucleic acids are baked onto the membrane in a vacuum oven at 80 0 C for 2-3 hours. Before use, the membrane is incubated overnight at 42 0 C in prehybridization buffer (5 x SSPE, 50%(v/v) formamide, 0.2% SDS, 5 x Denhardt's polyvinylpyrrolidone, 0.1% Ficoll 400 M (Pharmacia LKB, Piscataway, NJ), 15 0.1% bovine serum albumin)).
The hybridization probe for codon optimized AaIT gene constructs is a 3 2 P-labeled double-stranded DNA prepared by annealing oligonucleotides El and E2 (described in Example 2) and then filling in the single-stranded regions with phage T7 DNA polymerase in the presence of "Plabeled dATP and unlabelled dCTP, dGTP and TTP. The radiolabelled probe is denatured by heating and then diluted in hybridization buffer (prehybridization 25 buffer supplemented with 100 Ag/ml sheared and denatured salmon sperm DNA). The membrane is placed in the probe-containing hybridization buffer and incubated at 37 0 C for 16 hours. Unhybridized probe is then removed through four successive 20-30 minute washes: two at room temperature in 2 x SSPE, 0.2% SDS, and two at 65°C in 0.2 x SSPE, 0.2% SDS.
Excess fluid is removed from the membrane and the membrane-bound radioactivity is detected by autoradiography using Kodak XAR medical X-ray film in the presence of an DuPont Cronex (Wilmington, 44 DE) Lightning Plus intensifying screen. Using this assay, the presence of the AaIT gene is confirmed in 93% of the putative codon optimized AaIT-virus isolates examined.
Example 7 Confirmation of Recombinant Viruses Using the Polvmerase Chain Reaction (PCR) To verify that the putative native AaIT recombinant viruses contain an insert of the correct size, the distance between two known marker sites flanking the site of AaIT gene insertion is measured by PCR analysis of budded virus. The procedure is a modification of that described by B. Malitschek and M. Schartl The primers for this analysis are 15 located 84 to 110 bases upstream GCTGATATCATGGAG-3'; PVLForward) and 205 to 226 bases downstream (5'-GGATTTCCTTGAAGAGAGTGAG-3'; PVLReverse) of the AcMNPV polyhedrin gene translational start site.
To prepare virus samples for analysis, 4 il aliquots of each P1 stock, and of the wild-type AcMNPV E2 strain as a control, are each mixed in a GeneAmp tube (Perkin-Elmer/Cetus, Norwalk, CT) with 21 Al of Buffer A (10 mM Tris-HCl (pH 40 mM KC1, 0.1 mg/ml gelatin, 0.45%(v/v) of Nonidet T (Shell Oil 0.45% Tween 20 (ICI Americas)) supplemented with 200 Ag/ml of a nonspecific protease from Streptomyces griseus. Each tube is then incubated in a Perkin-Elmer/Cetus
DNA
Thermal Cycler running a single cycle three temperature program: 55 0 C for 60 minutes, (2) for 12 minutes, and soak at 4 0 C. The 45 function of this program is to liberate the viral DNA from the budded virus and to destroy the pronase prior to the PCR amplification step.
Each sample is prepared for the amplification reaction by adding 24.5 Al of a solution containing 1 x Buffer A, 3.0 mM MgCl 2 400 M dATP, 400 lM dGTP, 400 AM dCTP, 400 AM TTP, pmol primer 1 (PVLForward), 50 pmol primer 2 (PVLReverse). The PCR is initiated by adding 0.5 Al (2.5 units) of AmpliTaq DNA polymerase (Perkin- Elmer/Cetus) and starting a thermal cycler program consisting of 25-35 temperature cycles, wherein each cycle consists of 1 minute at 94 0 C, minutes at 55 0 C, and 2.5-3.0 minutes at 720C.
15 On the last cycle, the incubation time at 72 0 C is extended an additional 7 minutes, and the samples are then soaked at 4 0 C. An aliquot of each PCR reaction is then analyzed by gel electrophoresis in the presence of a suitable set of DNA size markers.
Each of four different putative native AaIT recombinant viruses tested by this method yields a single PCR product, the mobility of which is identical among the different samples and commensurate with the predicted size of 493 bp for 25 the fragment being amplified. This fragment contains the primers flanking the site of gene insertion. Similarly, a single PCR product is obtained with the wild-type AcMNPV strain E2 virus, and its mobility is in good agreement with the predicted size of 337 bp.
Example 8 Analysis of RNA Levels in Virus-Infected Cells Expression of the AaIT gene in Sf9 cells 46 infected with the codon optimized and native AaITviruses is estimated by Northern blot analysis of total cellular RNA isolated from virus-infected cells. Total cell RNA is isolated by the guanidine thiocyanate/CsCl procedure (36,37).
In this procedure, Sf9 cells (5 x 10 7 in a 150 cm 2 flask) are infected with virus at an MOI of PFU/cell and incubated at 27 0 C for 24 hours. The cells are then harvested by centrifugation (2000 rpm for 10 minutes in a Beckman GPR centrifuge) and the cell pellet is resuspended in 10 ml of 4 M guanidine thiocyanate solution (50% guanidine thiocyanate, 0.5% N-laurylsarcosine, 0.7% P-mercaptoethanol, 25 mM sodium citrate (pH 15 Total RNA is then partially purified by sedimentation through a 5.7 M CsCl, 0.1 M EDTA pad in a Beckman 70.1Ti rotor spun at 60,000 rpm for hours. The RNA pellet is redissolved in 2 ml TES buffer (10 mM Tris-HCl (pH 5 mM EDTA, 1% (w/v) SDS) and incubated for 5-10 minutes at 55 0 C to aid dissolution of the sample. The solution is then adjusted to 0.15 M NaCI and extracted once with water-saturated phenol. The aqueous phase is removed and the organic phase is re-extracted twice 25 more with 2 ml TES, 0.15 M NaC1. The aqueous phases are then combined and the RNA is precipitated with ethanol. The RNA pellet is redissolved in 2 ml H 2 0 and reprecipitated overnight at 4 0 C with an equal volume of 4 M LiCl. The pellet is then washed once with ice cold 2 M LiCl and redissolved in 0.5 ml Residual LiCl is then removed by one last ethanol precipitation and the final pellet is redissolved in 0.2 ml H 2 0. The RNA yield is determined by UV spectroscopy.
For Northern analysis 20 gg of each RNA is 47 size fractionated by electrophoresis on a 1% agarose gel containing 2.7 M formaldehyde, 40 mM MOPS (4morpholinepropanesulfonic acid) (pH 10 mM sodium citrate, 1 mM EDTA. The RNA is then transferred by capillary blotting to a nitrocellulose membrane (Schleicher and Schuell in the presence of 20 x SSC (3 M NaCI, 0.3 M sodium citrate; adjusted to pH 7.0 with NaOH). The membrane is prehybridized briefly in hybridization buffer (50% formamide, 0.9 M NaC1, 50 mM sodium phosphate (pH 5 mM EDTA, 0.1% (w/v) SDS, 4 x Denhardt's, 0.4 mg/ml tRNA, 0.25 mg/ml calf thymus DNA) and then hybridized for 16 hours at 42 0
C
in the same buffer containing a 32P-labeled DNA probe 15 prepared by random priming (38) a 464 bp Bam HI to Kpn I restriction fragment lying immediately 3' to the site of AaIT gene insertion in the AcMNPV polyhedrin gene. Following hybridization, unbound probe is removed by four successive 30 minute washes with 0.25 x SSC, 0.1% SDS at 65 0 C. A digitized image of the membrane-bound probe is produced by autoradiography using a Molecular Dynamics PhosphorImager
T
and individual bands are quantified using ImageQuant T v3.15 software (Molecular 25 Dynamics, Sunnyvale, CA).
Figure 4 summarizes an analysis of S: AaIT/polyhedrin RNA levels in Sf9 cells infected with wild-type AcMNPV (labelled "wild-type") and with the codon optimized (labelled with the specific heterologous signal sequence) and native (labelled grp III AaIT) recombinant viruses. Only one species of polyhedrin-containing RNA is detected in each sample and all are of a size which is appropriate for the structure of the polyhedrin or AaIT/polyhedrin gene present in the virus. The 48 amount of AaIT/polyhedrin RNA detected in the codon optimized AaIT-virus-infected cells ranges from 67% of the level of polyhedrin RNA accumulated in wild-type AcMNPV-infected cells. The corresponding value for native AaIT-virus-infected cells is This analysis shows that the AaIT/polyhedrin gene is correctly utilized and highly active in AaIT-virusinfected Sf9 cells.
Example 9 Production of Biologically Active AaIT in Virus-Infected Sf9 Cells AaIT causes an acute excitatory (contractile) paralysis when 1 ng or more is injected into the dorsolateral area of Sarcophaqa 15 arqyrostoma (flesh fly) larvae (39) A similar assay, using Musca domestica (house fly) larvae, is used to determine whether a detectable amount (1 ng) of biologically active AaIT is present in either the culture medium or cell pellets obtained during the 20 preparation of the codon optimized AaIT viral P1 stocks.
To assay the culture medium, 2-6 sl of each P1 stock (600-1000 cell equivalents/Al) are injected into the dorsolateral area M. domestica 25 larvae using a Hamilton syringe equipped with a 26 gauge needle. Larvae are examined five seconds after injection for evidence of involuntary contraction of body segments. Five larvae are assayed for each virus.
To assay AaIT activity in the cell pellets, the virus-infected Sf9 cells are washed once by centrifugation and the resuspended at a density of 30,000 cells per microliter in Dulbecco's 49 phosphate buffered saline (D-PBS). An aliquot of the cell suspension is removed and frozen on dry ice and then thawed at 37 0 C three times in quick succession. Two microliters of the freeze/thaw lysate 60,000 cell equivalents) are then injected into M. domestica larvae as described above and examined for acute contraction of body segments.
The table below summarizes the results obtained with an interleukin-2 signal-AaIT-virus mutant (containing a frame shift mutation) and three heterologous signal-codon optimized AaIT-virus isolates. Biologically active AaIT cannot be detected in any of the P1 stocks (cell culture supernatants) tested in this assay, indicating that 15 the concentration of active toxin is in the range of 0.2 ng/il or less in the supernatants. In contrast, AaIT is easily detected in 13 of 17 cell pellet 66 lysates. Three of the four negative lysates are derived from the mutant IL2-AaIT-virus isolates, which contain a frame shift mutation at position 265 in the toxin gene coding region. The other negative is obtained with isolate T9.4.1 (putative Cuticle- AaIT), which is negative by dot blot hybridization for the AaIT gene insert. The other four putative 25 Cuticle-AaIT constructs give positive results, as do all nine of the Esterase-6-AaIT and adipokinetic Shormone-AaIT constructs.
50 Isolate No. AaIT Gene Dot Blot Super- cell natant Pellet Mockc infected None 0/5 T6.1.1 IL2-AaIT 0/5 T6.2.1 [mutant] 0/5 T6.5.1 0/5 T7.2.1 Es6-AaIT 0/5 T7 .3.1 0/5 T7.4.1 0/5 T7.5.1 0/5 T8.1.1 ADK-AaIT 0/5 T8.2.1 0/5 T8.3.1 0/5 T8.4.1 0/5 T8.5.1 0/5 T9.1.1 Cuticle- 0/5 T9.2.1 AaIT+0/55 T9.3.1 0/5 T9.4.1 0/5 T9.5.1 0/5 0*
S
06 0 ego.
S0 6
S@
0 60 0 0@g
C
56
S
S
@6
S
S
0 Example Analysis of Virus Performance by Iniection into Larvae To test whether insertion of the AaIT gene enhances AcMNPV performance, budded virus prepared from the codon optimized Cuticle-AaIT and from the wild-type E2 strain of AcMNPV without the AaIT gene 51 are bioassayed by injection into mid-fourth instar Heliothis virescens (tobacco bud worm) larvae. Each virus is titered by the plaque assay method, as described by M. D. Summers and G. E. Smith and then diluted to 2 x 107, 2 x 106, and 2 x 10 5 PFU/ml in TNM-FH medium supplemented with 0.5% red dye number 5. Each larva is anesthetized with carbon dioxide for 2-5 minutes and then injected with 0.5 sl of diluted virus, using a Hamilton syringe equipped with a 26 gauge needle. The needle is inserted longitudinally between the last two prolegs and then moved anteriorly two to three body segments prior to injection. Following injection, each larva is inspected for the release of dyestained hemolymph and discarded if sample loss is evident or suspected. The larvae are then stored at 27 0 C in covered 4 cm 2 diet cells (one larva per cell) and inspected 2-3 times daily for evidence of morbidity or mortality. An individual is scored as 20 moribund (positive response) if it is unable to right itself within 0.5-2 minutes after being turned on its back.
Figure 5 summarizes the results obtained when H. virescens larvae are injected with 102, 103 25 and 104 PFU of each virus. Forty-eight larvae are used for each virus dose. Eighty insects ("No Virus") are injected with TNM-FH alone as a negative control. The results show that the Cuticle-AaIT AcMNPV kills its host faster than the wild-type AcMNPV at each of the doses tested. At 104 PFU, the
LT
5 for the wild-type virus is approximately 97 hours, whereas the corresponding
LT,
0 for the Cuticle-AaIT AcMNPV is 67 hours. Moreover, virtually all responding larvae infected with Cuticle-AaIT, but not those infected with the wild- 52 type AcMNPV, suffer from contractile paralysis prior to death. This result shows that insertion of the AaIT gene and the cuticle signal sequence into AcMNPV accelerates the speed of kill through the expression of biologically active toxin.
Example 11 Further Analysis of Virus Performance by Injection into Larvae The procedure of Example 10 is repeated by injecting separate groups of early fifth instar Heliothis virescens larvae with 104 PFU of budded virus prepared from either the wild-type E2 strain of AcMNPV without the AaIT gene, a native AaIT signal-native AaIT gene-AcMNPV construct, or one of seven different codon optimized heterologous signal- AaIT-AcMNPV constructs. A given virus is administered to 32 larvae. Three separate assays are conducted. Larvae damaged by reason of the injection are not included in the analysis. The 20 data are pooled and the results are depicted in the following Table: *eo *e e S S S S S S. S S S
S..
Bioassay Analysis of Recombinant AaIT-AcMNPV Isolates Injected Into lOd-Ild Heliothis virescens larvae Virus Signal n df 1(05%) LT5O L2(95%) AcMNPV-E2 N/A 81 5 123.8 126.0 128.2 AcMNPVrEs6/AaIT IEsterase-6 91 5 67.2 68.5 69.9 AcMNPV--ADK/AaIT Adipokinetic 81 6 72.7 76.3 80.2 AcMNPV-Cut/AaIT Cuticle 95 2 66.9 68.0 69.1 AcMNPV-Chor/AaIT Choriorn 89 7 77.3 79.0 80.8 AcMNPV-PBM/AaIT pBmHPC-12 87 4 87.9 89.6 91.5 AcMNPV-Apo/AaIT Apolipophorin 111 92 4 85.7 87.4 89.1 AcMNPV-Sex/AaIT SexSpecific 87 5 77.2 78.7 80.1 AcMNPV-AaIT/cDNA AaH ITI 85 6 72.5 74.1 75.7 54 In the Table, represents the total number of larvae from the three assays, "df" represents the degrees of freedom, means not applicable, and and represent the confidence limits of the data, such that if the assay was rerun with an equal number of larvae, there would be a 95% confidence level that the LT 0 would fall within the values shown for L1 and L2.
The results show that each of the codon optimized heterologous signal-AaIT-AcMNPV constructs (as well as the native AaIT signal-native AaIT gene- AcMNPV construct) kills its host faster than the wild-type AcMNPV. The LT, 0 for the wild-type virus is approximately 126 hours, whereas the corresponding LT, 0 for the seven heterologous signal- AaIT-AcMNPV constructs range from approximately 68- 89 hours and the native AaIT-AcMNPV construct has an
LT
5 of approximately 74 hours. These results confirm the results of Example 10 that insertion of 20 the AaIT gene and a heterologous signal sequence into AcMNPV accelerates the speed of kill through the expression of biologically active toxin.
Example 12 Co-Occlusion of Wild-Type and Occlusion- 25 Negative Recombinant Viruses In Viral Polyhedra Because the recombinant AaIT-viruses are defective for the production of polyhedrin, polyhedra containing a mixture of wild-type and recombinant virions are prepared by co-infecting Sf9 cells with the recombinant AaIT-virus and a wildtype helper virus the E2 strain of AcMNPV).
To determine the amount of each virus to use for coinfection, 2 x 107 Sf9 cells are seeded in a 150 cm 2 55 flask and infected with various amounts of the wildtype and recombinant viruses, each at a multiplicity of infection (MOI) of at least 1 plaque forming units (PFU) per cell. Four days later, the cells are counted and the percentage of cells with clearly discernible viral occlusions in the cell nucleus is determined by microscopic visualization. The total number of polyhedra is also determined by counting polyhedra in samples treated with 0.2% Triton X-100 and 2% SDS. The results of one such analysis involving the co-occlusion of wild-type E2 AcMNPV and the cuticle-AaIT recombinant AcMNPV are summarized in the following Table:
S..
Culture MOI Total Percent of Total No. [WT:Cut-AaIT] cells cells with polyhedra Polyhedra x 10' occlusions x 108 per cell 1 10:0 2.15 94 4.10 19.0 2 10:1 1.85 92 3.65 19.7 3 10:2 2.30 89 3.30 14.3 4 5:5 1.85 74 2.15 11.6 5 2:10 2.00 36 0.55 2.75 6 2:20 2.10 23 0.12 0.57.
These results demonstrate that even when the MOI of the wild-type virus is at least 2 PFU per cell, both the percentage of cells with viral polyhedra (occlusions) and the average number of polyhedra per cell decrease significantly as the MOI of the recombinant virus is increased. To maintain a large fraction of recombinant virions per polyhedron without making unacceptable sacrifices in the yield of polyhedra, all subsequent co-occlusion experiments are done with both viruses wild- 56 type and occlusion-negative recombinant) at an MOI of 3 each.
Example 13 Microdrop Bioassay to Measure the Oral Activity of Codon Optimized and Native Sequence Recombinant AaIT-Viruses Co-occluded into Polyhedra with Wild-Type AcMNPV To examine the oral toxicity of the recombinant AcMNPV containing a codon optimized or native sequence encoding AaIT, each virus (with the exception of the IL-2/AaIT recombinant, which is not assayed) is co-occluded with wild-type AcMNPV into viral polyhedra (see Example 12) and fed to second 15 instar Heliothis virescens larvae using a microdrop bioassay procedure as follows. Individual second instar Heliothis virescens larvae are transferred into empty assay wells containing a disk of prewetted filter paper. One larva is placed per well. The larvae are then stored at 26 0 C, relative humidity for 12 to 20 hours (overnight).
The next day, a 15 ml aliquot of Stoneville insect diet (40) is heated to boiling.
Five mls of water are added to the melted diet.
25 This mixture is reheated to boiling and promptly centrifuged at low speed. Supernatant is removed and a few drops of food dye are added to the clarified supernatant as an aid to visualize the diet. The molten diet is aliquoted into microfuge tubes, respun in a Beckman microfuge, and the clarified supernatant is transferred into new microfuge tubes. This molten diet is placed in a heat block at 54 0 C until needed.
After the diet cools to 54 0 C, the desired 57 amount of PIBs is added. Typically, this ranges from 10 to 250 PIBs per Al. After mixing well, 1 Al drops of treated diet are aliquoted onto PARAFILM
T
(American National Can, Greenwich, CT), where they harden. The hardened drops are quickly transferred to the wells containing the individual larvae, one drop per larva. The larvae are allowed to feed for 2 hours and those larvae which consume the entire microdrop are placed into a new assay well containing a standard amount of untreated Stoneville diet. Larvae are then placed at 26 0 C, 50% relative humidity, and monitored twice daily for paralysis and death. Paralysis is determined by rolling larvae onto their backs and observing for seconds. If the larva remains on its back, it is considered moribund. Moribund larvae generally die during the 24 hours following diagnosis. The duration of the test is generally 8 days.
Larvae are inspected two to three times 20 daily and scored for evidence of morbidity and mortality. Both dead and moribund larvae are scored as responding to the treatment. Figures 6-15 summarize the results obtained with each of the viruses.
25 With one exception, all of the recombinant viruses demonstrate an earlier onset of response than the wild-type AcMNPV (which lacks the AaIT gene). The exception is the AcMNPV construct containing the pBMHPC-12 signal sequence linked to the codon optimized cDNA encoding AaIT, which performs approximately the same as the wild-type AcMNPV. The actual ratio of wild-type to recombinant virus in the polyhedra and in the infected insects is not analyzed.
58 Bibliocgraph 1. Tomaiski, M. and Miller, L. K., Nature, 352, 82-85 (1991).
2. Federici, B. In Vitro, 28, (1992).
Envir. Microbiolocw 56, 2764-2770 (1990).
4. Luckow, V. and Summmers, M. D., Bio/Technolo, 47-53 (1988).
5. Miller, L. Ann. Rev. Microbiol., 42, 177-199 (1988).
6. Smith, G. and Summers, M. D., U.S. Patent Number 4,745,051.
7. Granados, R. and Federici, B. A., The Biologry of Baculoviruses, L, 99 (1986).
8. Grantham, et al., Nuci. Acids 8, 49-62 (1980).
9. Grantham, et al., Nuci. Acids Res., 9, 43-74 (1981).
10. Maroyala, et al., Nuci. Acids 14, 151-197 (1986).
11. Aota, et al., Nuci. Acids Res., 16, 315-402 (1988).
12. Wada, et al., Nuci. Acids Res., 19 Supp., 1981-1985 (1991).
13. Kurland, FEBS Letters, 285, 165-169 (1991).
14. Pedersen, EMBO 3, 2895-2898 (1984).
15. Sorensen, J. Mol. Biol., 207, 365-377 (1989).
16. Randall, et al., Eur. J.
Biochem., 107, 375-379 (1980).
17. Curran, and Yarus, J. Mol.
59 Biol., 209, 65-77 (1989).
18. Varenne, et al., J. Mo1. Biol., .180, 549-576 (1984).
19. Garel, J. Theor. Biol., 43, 211-225 (1974).
Ikemura, J. Mol. Biol., 146, 1-21 (1981).
21. Ikemura, J. Mo1. Biol., 151, 389- 409 (1981).
22. Hooft van Iddekinge, et al., Virology, 131, 561-565 (1983).
23. Kuzic, et al., Virolo~v 139, 414-418 (1984).
24. Ikemura, Mol. Biol. Evol., 2, 13- 24 (1985).
25. Summers, M. and Smith, G. A Manual Of Methods For Baculovirus Vectors And Insect Cell Culture Procedures, pages 35, 38-42, Dept. of Entomology, Texas Agricultural Experiment Station *and Texas A M University, College Station, Texas 77843-2475, Texas Agricultural Experiment Station Bulletin No. 1555 (1987).
26. Smith, G. and Summers, M. J.
Virol., 33, 311-319 (1980).
25 27. Smith, G. and Summers, M. D., Virolo, 89, 519-527 (1978).
28. Summers, M. U.S. Patent Number C*5,155, 037.
29. von Heijne, Nuc. Acids Res., 14, 4683-4690 (1986).
Dee, et al., Bio/Technolov 8, 339-342 (1990).
31. Luckow, V. and Summers, M. D., Virology, 170, 31-39 (1989).
32. Samibrook, et al., Molecular 60 Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
(1989).
33. Webb, N. and Summers, M. J.
Methods Cell Molec. Biol., 2, 173-188 (1990).
34. Grace, T. C. Nature, 195, 788-789 (1962).
Malitschek, and Scharti, M., BioTechnicrues, 11, 177-178 (1991) 36. Glisin, et al., Biochemistry 13, 2633 -2638 (1974) 37. Chirgwin, et al., Biochemistry, 18, 5294-5299 (1979).
38. Feinberg, A. and Vogelstein, B., Anal. Biochem., 132, 6-13 (1983).
39. Zlotkin, et al., Toxicon, 9, 1-8 (19 71).
King, E. and Hartley, G. G., "Heliothis virescens", in Handbook of Insect Rearing Vol. II, Singh, and Moore, R. eds., pages 323-328 (Elsevier, 1985).
Claims (11)
1. An isolated codon optimized nucleic acid sequence encoding Androctonus australis insect toxin (AaIT), wherein said sequence is the following: AAG AAG AAC GGC TAC GCA GTC GAC TCA TCC GGA AAA GCC CCC GAG TGC CTG CTC TCG AAC TAT TGC AAC AAT GAA TGC ACC AAG GTG CAC TAC GCT GAC AAG GGC TAC TGT TGC CTT CTG TCC TGC TAT TGC TTC GGT CTC AAC GAC GAC AAG AAA GTT CTG GAA ATC TCT GAT ACT CGC AAG AGC TAC TGT GAC ACC ACC ATC ATT AAC TAA.
2. An expression vector which contains the nucleic acid sequence of Claim 1.
3. The expression vector of Claim 2 15 wherein the expression vector is an insect virus. S4. The expression vector of Claim 3 wherein the insect virus is selected from the group consisting of nuclear polyhedrosis viruses, granulosis viruses, non-occluded viruses and entomopox viruses. The expression vector of Claim 4 wherein the insect virus is a: nuclear polyhedrosis virus selected from the group consisting of Lymantria dispar NPV (gypsy moth NPV), Autogcrapha californica MUPV, Syncrapha falcifera NPV (celery looper NPV), Spodoptera litturalis NPV, Spodoptera fruqcriperda NPV, Heliothis armigera NPV, Mamestra brassicae NPV, Choristoneura fumiferana NPV, Trichoplusia ni NPV and Heliocoverpa zea NPV; granulosis virus selected from the group consisting of Cydia pomonella GV (coddling 62 moth GV), Pieris brassicae GV and Trichoplusia ni GV; non-occluded virus selected from the group consisting of Orcvtes rhinoceros NOV and Heliothis zea NOV; or entomopox virus selected from the group consisting of Melolontha melonotha EPV, Amsacta moorei EPV, Locusta migratoria EPV, Melanoplus sanquinipes EPV, Schistocerca qreqaria EPV, Aedes aeqyvti EPV and Chironomus luridus EPV.
6. The expression vector of Claim wherein the nuclear polyhedrosis virus is Autoqrapha californica MNPV.
7. An expression vector which comprises the nucleic acid sequence of Claim 1 inserted into a baculovirus transfer vector.
8. A host cell transformed with the nucleic acid sequence of Claim 1.
9. The host cell of Claim 8 wherein the host cell is an insect cell.
10. A method of producing AaIT which 20 comprises transforming or infecting a host cell with the nucleic acid sequence of Claim 1, and culturing the host cell under conditions which permit a: expression of said nucleic acid sequence by the host cell. 25 11. The method of Claim 10 in which the host cell is an insect cell.
12. A method for protecting plants from damage from insects, which comprises.delivering to said plant an insect virus containing the codon optimized nucleic acid sequence as follows: AAG AAG AAC GGC TAC GCA GTC GAC TCA TCC GGA AAA GCC CCC GAG TGC CTG CTC TCG AAC TAT TGC AAC AAT GAA TGC ACC AAG GTG CAC TAC GCT GAC AAG GGC TAC TGT TGC CTT CTG TCC TGC TAT TGC TTC GGT CTC AAC GAC GAC AAG AAA GTT CTG GAA ATC TCT GAT ACT CGC AAG AGC TAC TGT GAC 63 ACC ACC ATC ATT AAC TAA
13. An isolated codon optimised nucleic acid sequence encoding Androctonus auslralis insect toxin (AsIT) substantially as hereinbefore described with reference to any one of the examples.
14. A method of producing AaIT which comprises culturing a host cell which has been transformed or infected with a codon optimised nucleic acid sequence encoding AalT, which method is substantially as hereinbefore described with reference to any one of the examples. Dated 3 May, 2000 '0 American Cyanamid Company Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON *e .o "3AV
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU48372/97A AU721364B2 (en) | 1993-01-25 | 1997-12-15 | Codon optimized DNA sequence for insect toxin AaIT |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US926493A | 1993-01-25 | 1993-01-25 | |
| US009264 | 1993-01-25 | ||
| AU53967/94A AU5396794A (en) | 1993-01-25 | 1994-01-24 | Codon optimized DNA sequence for insect toxin AaIT |
| AU48372/97A AU721364B2 (en) | 1993-01-25 | 1997-12-15 | Codon optimized DNA sequence for insect toxin AaIT |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU53967/94A Division AU5396794A (en) | 1993-01-25 | 1994-01-24 | Codon optimized DNA sequence for insect toxin AaIT |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU4837297A AU4837297A (en) | 1998-03-12 |
| AU721364B2 true AU721364B2 (en) | 2000-06-29 |
Family
ID=25630291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU48372/97A Ceased AU721364B2 (en) | 1993-01-25 | 1997-12-15 | Codon optimized DNA sequence for insect toxin AaIT |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU721364B2 (en) |
-
1997
- 1997-12-15 AU AU48372/97A patent/AU721364B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU4837297A (en) | 1998-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5547871A (en) | Heterologous signal sequences for secretion of insect controlling proteins | |
| CA2093335C (en) | Insect-specific paralytic neurotoxin genes for use in biological insect control: methods and composition | |
| US6096304A (en) | Recombinant baculovirus insecticides | |
| AU742821B2 (en) | Novel recombinant baculovirus, construction method thereof and insect pesticidal composition containing the same | |
| EP0621337A1 (en) | Codon optimized DNA sequence for insect toxin AaIT | |
| US6087165A (en) | Recombinant baculovirus and its use as a biocontrol agent for crop pests | |
| AU753930B2 (en) | Recombinant baculovirus-based insecticides | |
| Ma et al. | Baculovirus expression of an insect gene that encodes multiple neuropeptides | |
| US5674485A (en) | Insect diagnostic and control compositions with truncated JHE | |
| CA2213444A1 (en) | Insecticidal toxins from bracon hebetor | |
| CA2228195C (en) | Transgenic insect virus for use as a biopesticide | |
| CA2103901A1 (en) | Insecticidally effective peptides isolatable from diguetia spider venom | |
| AU721364B2 (en) | Codon optimized DNA sequence for insect toxin AaIT | |
| AU720082B2 (en) | Heterologous signal sequences for secretion of insect controlling toxins | |
| KR19990076627A (en) | Preparation of Recombinant Baculovirus | |
| JPH09510871A (en) | Biological insect control agent | |
| CA2141206A1 (en) | Gene insertion by direct ligation in vitro | |
| AU675939B2 (en) | Recombinant insect virus with reduced capacity for host-to-host transmission in the environment and methods to produce said virus | |
| MXPA98000646A (en) | Transgen virus | |
| MXPA00010981A (en) | Recombinant baculovirus-based insecticides | |
| Xinwen | Genomics and Genetic Engineering of Helicoverpa Armigera Nucleopolyhedrovirus | |
| MXPA98004689A (en) | Production of baculovirus recombinan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |